Mosaic ImmunoEngineering Inc.

CPMV: 10-Q · periodic report

Mosaic ImmunoEngineering filed its 10-Q for the quarter ended June 30, 2026 disclosing just $26 in cash and cash equivalents and a going-concern warning, stating that cash on hand will not satisfy operational and capital requirements through twelve months from the filing date. The pre-revenue cancer immunotherapy developer reported a Q2 2026 net loss of $177,496 and a six-month net loss of $352,847, with total liabilities of $7.8 million against total assets of only $3,278, producing a stockholders' deficit of $7.8 million and an accumulated deficit of $9.9 million. Pipeline options have narrowed: the $15.0 million binding term sheet with Oncotelic Therapeutics expired on June 30, 2025, and the CWRU license covering lead candidate MIE-101 was terminated in March 2024 after non-payment of amounts owed. Management says it is in discussions with potential investors and strategic partners, but warns the company may need to curtail or cease operations completely if adequate funding is not secured.

SEC 10-Q•2mo ago

CPMV: 10-Q · periodic report

Mosaic ImmunoEngineering reported a net loss of $175,351 for the quarter ended March 31, 2026, with cash and cash equivalents dwindling to just $72. The company has no revenue and faces substantial doubt regarding its ability to continue as a going concern, explicitly stating that current cash will not satisfy operational requirements for the next twelve months. The balance sheet reveals a stockholders' deficit of $7.65 million, driven by $4.37 million in accrued compensation and $1.48 million in convertible notes. Management is actively seeking capital through debt or equity offerings, but has no current financing arrangements in place, raising the risk of operational cessation or highly dilutive emergency fundraising. A binding term sheet for a $15 million acquisition of assets from Oncotelic Therapeutics expired in June 2025 without closing, leaving the company without a near-term pipeline catalyst. The company remains dependent on raising significant capital to advance its immunotherapy programs, including its lead candidate MIE-101, amidst severe liquidity constraints.

SEC 10-Q•5mo ago

CPMV: NT 10-Q · late filing

Mosaic ImmunoEngineering, Inc. filed a Form 12b-25 notification on May 15, 2026, stating it is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, by the prescribed deadline. The company cited that additional time, resources, and effort are required to complete work related to its financial reporting and close procedures. Mosaic expects to file the delayed 10-Q as soon as possible, but no later than the fifth calendar day following the prescribed due date, which is May 20, 2026.

SEC NT 10-Q•5mo ago